WallStSmart

Abbott Laboratories (ABT)vsBruker Corporation (BRKR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1247% more annual revenue ($46.59B vs $3.46B). ABT leads profitability with a 11.7% profit margin vs -0.3%. BRKR appears more attractively valued with a PEG of 1.52. ABT earns a higher WallStSmart Score of 52/100 (C-).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

BRKR

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-43.2%)

Margin of Safety

-43.2%

Fair Value

$73.84

Current Price

$107.81

$33.97 premium

UndervaluedFair: $73.84Overvalued
BRKRUndervalued (+5.0%)

Margin of Safety

+5.0%

Fair Value

$44.67

Current Price

$53.41

$8.74 discount

UndervaluedFair: $44.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$182.49B9/10

Large-cap with strong market position

BRKR0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.134/10

Expensive relative to growth rate

P/E RatioValuation
34.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

BRKR4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : BRKR

BRKR has a balanced fundamental profile.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : BRKR

The primary concerns for BRKR are PEG Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while BRKR is a turnaround play — different risk/reward profiles.

BRKR carries more volatility with a beta of 1.29 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (52/100 vs 35/100) and 13.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Bruker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?